🔗 Permalink

Inventor profile of:

Alan Gill

City:

Reading, Massachusetts

Country:

United States

Published Applications:

Last publication date:

2025-08-21

Top Assignees for applications by Alan Gill

The entities that hold a legal rights for patent applications filed by inventor Gill Alan:

ALS THERAPY DEVELOPMENT INSTITUTE 11 Cambridge, MA United States
Biogen Idec MA Inc. 2 Cambridge, MA United States
ALS THERAPY DEVELOPMENT INSTITUTE 1 Watertown, MA United States
Biogen Idec MA Inc. 1 Canbridge, MA United States

Recent patent applications by Gill Alan

Alan Gill from Reading, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-08-21

US20250263493A1

Chemistry; metallurgy

ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L-RELATED DISEASES OR DISORDERS

#2 | 2024-02-08

US20240043549A1

Chemistry; metallurgy

Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders

#3 | 2024-01-18

US20240016879A1

Human necessities

COPPER COMPLEXES FOR TREATMENT OF NEURODEGENERATIVE DISORDERS

#4 | 2023-11-30

US20230382890A1

Chemistry; metallurgy

Targeting of endoplasmic reticulum dysfunction and protein folding stress to treat neurological conditions

#5 | 2021-09-02

US20210269538A1

Chemistry; metallurgy

Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders

#6 | 2021-02-11

US20210038676A1

Human necessities

Copper complexes for treatment of neurodegenerative disorders

#7 | 2021-01-14

US20210009558A1

Chemistry; metallurgy

Targeting of endoplasmic reticulum dysfunction and protein folding stress to treat neurological conditions

#8 | 2020-09-03

US20200277391A1

Chemistry; metallurgy

Anti-CD40L antibodies

#9 | 2019-03-28

US20190092868A1

Chemistry; metallurgy

Methods of treating a CD40L associated disease or disorder by administering anti-CD40L antibodies

#10 | 2017-11-30

US20170342158A1

Chemistry; metallurgy

Anti-CD40L antibodies

#11 | 2017-08-17

US20170231558A1

Human necessities

Measurement Of ALS Progression Based On Kinetic Data

#12 | 2013-11-07

US20130295092A1

Human necessities

Method for the treatment of neurodegenerative diseases

#13 | 2013-06-13

US20130150454A1

Chemistry; metallurgy

Targeting of T-lymphocytes to treat amyotrophic lateral sclerosis

#14 | 2012-09-20

US20120237505A1

Chemistry; metallurgy

Targeting of CD8+ T-lymphocytes to treat neurodegenerative diseases

#15 | 2011-12-01

US20110293612A1

Chemistry; metallurgy

Method for the treatment of neurodegenerative diseases

#16 | 2009-12-10

US20090304699A1

Human necessities

Method of treating lung fibrosis using ST2 polypeptide

#17 | 2006-06-22

US20060134102A1

Chemistry; metallurgy

Lymphotoxin beta receptor agents in combination with chemotherapeutic agents

InventorID:

517972 ⎘